Less Than 1% of FDA-Cleared AI Devices Tested for Clinical Benefits
OVERVIEWA TechTarget analysis reveals that less than 1% of FDA-cleared AI-enabled medical devices have been tested for clinical benefits in rigorous clinical trials, creating a massive evidence gap between regulatory authorization and clinical validation. This finding underscores a fundamental disconnect in the FDA's AI device oversight: devices receive clearance based on technical specifications and predicate device comparisons, but the agency does not require prospective clinical evidence demonstrating that the AI system improves patient outcomes. The gap is particularly troubling for AI systems that are intended to improve diagnosis or treatment decisions—areas where clinical efficacy should be the primary authorization criterion. The finding has prompted calls for FDA reform, including requirements for clinical outcome data and post-market surveillance protocols specifically designed for adaptive AI systems. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.